ZANIDATAMAB

UNII:	Z20OC92TDI
Formula:
Preferred Substance Name:	ZANIDATAMAB

2169946-15-8
ANTI-HER2 BI-SPECIFIC MONOCLONAL ANTIBODY ZW25
IMMUNOGLOBULIN G1, ANTI-(HUMAN TYROSINE KINASE RECEPTOR HER2) (HUMAN-MUS MUSCULUS BIPARATOPIC MONOCLONAL ZW25 LIGHT CHAIN VARIABLE REGION FRAGMENT) FUSION PROTEIN WITH PEPTIDE (SYNTHETIC 20-AMINO ACID LINKER) FUSION PROTEIN WITH HUMAN-MUS MUSCULUS BIPARATOPIC MONOCLONAL ZW25 HEAVY CHAIN VARIABLE REGION FRAGMENT FUSION PROTEIN WITH PEPTIDE (SYNTHETIC 2-AMINO ACID LINKER) FUSION PROTEIN WITH HUMAN FC FRAGMENT, (261->229'),(264->232')-BIS(DISULFIDE) WITH IMMUNOGLOBULIN G1 ANTI-(HUMAN TYROSINE KINASE RECEPTOR HER2) (HUMAN-MUS MUSCULUS BIPARATOPIC MONOCLONAL ZW25 .GAMMA.1-CHAIN) DISULFIDE WITH HUMAN-MUS MUSCULUS BIPARATOPIC MONOCLONAL ZW25 .KAPPA.-CHAIN
JZP598
ZANIDATAMAB [INN]
ZANIDATAMAB [USAN]
ZANIDATAMAB [WHO-DD]
ZANIDATAMAB HRII [WHO-DD]
ZANIDATAMAB-HRII
ZIIHERA
ZW25
ZW-25

Note

UNIIs are generated based on scientific identity characteristics using ISO 11238 data elements. UNII availability does not imply any regulatory review or approval. Synonyms and mappings are based on the best public information available at the time of publication. Please report any problems/errors associated with this data to FDA-SRS@fda.hhs.gov.

ZANIDATAMAB

Synonyms and Mappings

Resources